ArticleFrontiers in ophthalmology2026
Incidence and clinical characterization of retinal detachment in acute retinal necrosis: a global federated database analysis.
Article in Frontiers in ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To determine the incidence of retinal detachment (RD) following acute retinal necrosis (ARN) and to evaluate demographic and treatment-related associations using a large, multi-institutional database. Design: Retrospective cohort study. Methods: Setting: TriNetX Research Network. Study population: Patients diagnosed with ARN between January 1, 2014, and January 1, 2024. Procedures: ARN and RD were identified using ICD and CPT codes. Chi-square tests, risk ratio analyses, and logistic regression models were used to evaluate demographic and treatment-related associations of RD. Main outcome measures: Incidence and associations for RD at 3, 6, and 12 months post-diagnosis of ARN. Results: Among 1,785 patients with ARN, the overall incidence of RD was 12.49% (n=223), with 135 cases (60.5%) occurring within the first 3 months of diagnosis and 88 cases (39.5%) occurring thereafter. Although aggressive combination therapy consisting of systemic corticosteroids, oral valacyclovir, and/or intravitreal foscarnet was primarily used in severe cases, RD still occurred frequently. No significant differences were observed in RD incidence based on age, sex, diabetes status, or immunosuppression. Conclusions: In this large EHR-based cohort, RD following ARN occurred most commonly within the first 3 months after diagnosis. Treatment exposures (corticosteroids, valacyclovir, intravitreal foscarnet) should be interpreted strictly as proxies of disease severity, not independent risk factors for RD. These findings underscore the importance of close ophthalmic monitoring during the first 3 months after ARN diagnosis, when the risk of RD is highest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.